Fruita, Colorado, August 12, 2026
Neuralytix, LLC announced the full commercial availability of its iD3 System, an FDA 510(k)-cleared mechanomyography (MMG) platform designed to provide spine surgeons with real-time, objective feedback on neurophysiologic changes during decompression surgery. Following its initial commercial release in October 2025, the iD3 System is now available through Neuralytix’s U.S. distributor network, marking an important commercialization milestone for the company’s intraoperative nerve assessment technology. The system is designed to provide surgeons with quantitative information about nerve function during procedures, complementing traditional visual and anatomical assessments.
iD3 Provides Real-Time Nerve Assessment
The iD3 System uses mechanomyography technology to measure how nerves conduct and respond during spine surgery. According to Neuralytix, the platform provides surgeons with objective, real-time information on neurophysiologic changes occurring throughout nerve decompression procedures. The technology is intended to help address an important clinical question encountered during decompression surgery: whether a nerve has been adequately decompressed. Traditional assessments during spine procedures can rely heavily on visual inspection and anatomical judgment. Neuralytix developed iD3 to add a functional measurement to that assessment, providing quantitative information that may help surgeons evaluate changes in nerve function during the procedure. The company describes the approach as analogous to combining structural and functional assessments in other areas of medicine, where anatomical findings may not always fully reflect physiological function. The system is surgeon-directed, allowing it to be incorporated into existing surgical workflows without requiring a dedicated technician or neurophysiologist. This design is intended to make intraoperative nerve assessment more accessible to spine surgeons while minimizing additional personnel requirements during procedures.
FDA-Cleared Technology Supports Commercial Launch
The full commercial launch builds on the iD3 System’s previous U.S. market introduction in October 2025. Neuralytix states that the system has received FDA 510(k) clearance, with clearance identifiers K243636 and K260992. The latest commercial expansion makes the technology available through the company’s U.S. distributor network, supporting broader adoption among spine surgery practices. The system’s regulatory clearance and commercial availability represent important milestones for Neuralytix’s mechanomyography platform. By integrating nerve assessment directly into spine surgery, iD3 is designed to provide clinicians with functional information without requiring a separate neurophysiology workflow. The company’s approach focuses on delivering objective measurements while allowing the surgeon to remain in control of the assessment process.
Advertisement
MMG Technology Advances Functional Spine Surgery
Mechanomyography (MMG) forms the foundation of the iD3 System’s approach to intraoperative nerve assessment. The platform is designed to measure physiological responses associated with nerve function and translate those changes into quantitative feedback for the surgical team. Neuralytix believes this information can complement the anatomical information already available to surgeons during decompression procedures. The company’s commercialization strategy reflects a broader movement toward data-driven and objective intraoperative decision-making in surgery. As surgical technologies increasingly incorporate real-time measurements, platforms that provide functional information alongside anatomical visualization may help clinicians make more informed assessments during procedures. For spine surgery, where nerve decompression is a central objective of many procedures, real-time functional feedback could provide an additional dimension to the surgeon’s assessment. Neuralytix is focused on developing mechanomyography technology for intraoperative nerve assessment, with the iD3 System representing its primary commercial platform. The full U.S. commercial availability expands access to an FDA-cleared technology intended for use during spine surgery and represents the next stage in the company’s efforts to integrate objective nerve assessment into routine surgical workflows. As adoption expands, further clinical experience will help determine how the iD3 System influences surgical decision-making and patient outcomes in real-world spine procedures. For the MedTech sector, the launch highlights continued innovation in intraoperative monitoring, surgical guidance, and technologies designed to provide surgeons with objective physiological information during minimally invasive and decompression procedures.
Source: Neuralytix press release
